Luye Pharma Group (LYPHF) Stock Price, News & Analysis

Company Overview

Luye Pharma Group Ltd. is a China-based pharmaceutical company headquartered in Yantai, Shandong Province. Established in 1994, the company specializes in the research, development, manufacturing and marketing of a broad portfolio of medicaments and health-care products. Luye Pharma structures its operations across three main segments: innovative drugs, generic drugs and over-the-counter (OTC) health and wellness products. Through in-house R&D and strategic collaborations, the company aims to address unmet medical needs in both domestic and international markets.

The company’s product offerings encompass key therapeutic areas such as oncology, cardiovascular disease, gastroenterology and respiratory illnesses. Among its flagship products is S-1, an oral chemotherapy agent indicated for gastrointestinal cancers. Luye Pharma’s generic portfolio includes cardiovascular and antibiotic drugs that cater to significant volume markets in China. On the OTC side, the firm markets vitamin supplements and nutritional products designed for everyday health maintenance, leveraging an expanding sales network that reaches hospitals, retail pharmacies and e-commerce platforms.

Over more than two decades of operations, Luye Pharma has invested in building a vertically integrated supply chain with manufacturing facilities accredited under both Chinese and international quality standards. The company’s global footprint has grown to include commercial subsidiaries and distribution partnerships across Asia-Pacific, Europe and North America, reflecting its ambition to serve patients beyond its domestic base. Luye Pharma’s ongoing R&D pipeline features several clinical-stage candidates, underscoring its strategic focus on innovation.

Management at Luye Pharma emphasizes a balanced approach of organic growth and targeted alliances to accelerate late-stage drug development and market access. By maintaining a diversified product mix and further advancing its R&D capabilities, the company seeks to strengthen its position as a leading biopharmaceutical enterprise emerging from China’s rapidly evolving healthcare sector.

Key Stats

• Today's Range: $0.27 to $0.27
• 50-Day Range: $0.27 to $0.27
• 52-Week Range: $0.26 to $0.27
• Volume: N/A
• Average Volume: 100 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

LYPHF Stock Analysis - Frequently Asked Questions

How have LYPHF shares performed this year?

Luye Pharma Group's stock was trading at $0.3437 on January 1st, 2025. Since then, LYPHF stock has decreased by 22.0% and is now trading at $0.2680.

How do I buy shares of Luye Pharma Group?

Shares of LYPHF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:LYPHF
• CIK: N/A
• Web: www.luye.cn
• Phone: N/A
• Fax: N/A
• Employees: 5,234
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A